Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
HYMPAVZI’s safety profile was generally favorable
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Twelve hospitals across India will be part of the network which will support the trial in India
Subscribe To Our Newsletter & Stay Updated
